Wuxi Taxus Pharmaceutical Co., Ltd. is a biopharmaceutical company under Hodo Group Company. It is mainly engaged in the R &D, manufacture and sales of taxane anti-tumor API, dosage and anti-gout product allopurinol.
The company was founded in 2004 and has more than 210 employees. It established a research institute and hired overseas returnees to lead the research and development of new products, with more than 20 senior talents joined in. In July 2018, an international pharmaceutical R&D company was established in New York to develop and introduce new drugs with outstanding performance in foreign markets into China.
The company has built a yew high-tech industrial park of more than 30,000 Mu (6000 Acres), which is the largest yew seedling and planting base in China. It has GMP production workshops of more than 40,000 square meters, the products include: natural paclitaxel, 10-DAB III, semi-synthetic paclitaxel, docetaxel, cabazitaxel and other anti-tumor product series, as well as allopurinol and its intermediates.
Paclitaxel product’s DMF has obtained the US FDA list number (25759), and is registered and sale in South Korea, India, Iran, Belarus, Taiwan and other countries and regions with high reputation. It has MAH/CMO cooperation with many domestic and foreign listed companies as well.
The company was founded in 2004 and has more than 210 employees. It established a research institute and hired overseas returnees to lead the research and development of new products, with more than 20 senior talents joined in. In July 2018, an international pharmaceutical R&D company was established in New York to develop and introduce new drugs with outstanding performance in foreign markets into China.
The company has built a yew high-tech industrial park of more than 30,000 Mu (6000 Acres), which is the largest yew seedling and planting base in China. It has GMP production workshops of more than 40,000 square meters, the products include: natural paclitaxel, 10-DAB III, semi-synthetic paclitaxel, docetaxel, cabazitaxel and other anti-tumor product series, as well as allopurinol and its intermediates.
Paclitaxel product’s DMF has obtained the US FDA list number (25759), and is registered and sale in South Korea, India, Iran, Belarus, Taiwan and other countries and regions with high reputation. It has MAH/CMO cooperation with many domestic and foreign listed companies as well.
![Picture of 4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride 106261-49-8 Imatinib intermediate](https://ecasb.com/images/thumbs/default-image_415.png "Show details for 4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride 106261-49-8 Imatinib intermediate")